All the AF samples selected had high angiogenic potential (as measured by tubule formation assay) compared to samples from nondiabetic controls but had markedly lower VEGF levels than those in nondiabetic controls (table S1), consistent with their prior treatment with PRP and/or anti-VEGF therapy. This evidence concerns the gene VEGFA and atrial fibrillation.